| Literature DB >> 26873347 |
Dagmar Gotthardt1, Eva M Putz1, Eva Grundschober1, Michaela Prchal-Murphy1, Elisabeth Straka1, Petra Kudweis1, Gerwin Heller2, Zsuzsanna Bago-Horvath3, Agnieszka Witalisz-Siepracka4, Abbarna A Cumaraswamy5, Patrick T Gunning5, Birgit Strobl4, Mathias Müller4, Richard Moriggl6, Christian Stockmann7, Veronika Sexl8.
Abstract
UNLABELLED: Natural killer (NK) cells are tightly regulated by the JAK-STAT signaling pathway and cannot survive in the absence of STAT5. We now report that STAT5-deficient NK cells can be rescued by overexpression of BCL2. Our experiments define STAT5 as a master regulator of NK-cell proliferation and lytic functions. Although NK cells are generally responsible for killing tumor cells, the rescued STAT5-deficient NK cells promote tumor formation by producing enhanced levels of the angiogenic factor VEGFA. The importance of VEGFA produced by NK cells was verified by experiments with a conditional knockout of VEGFA in NK cells. We show that STAT5 normally represses the transcription of VEGFA in NK cells, in both mice and humans. These findings reveal that STAT5-directed therapies may have negative effects: In addition to impairing NK-cell-mediated tumor surveillance, they may even promote tumor growth by enhancing angiogenesis. SIGNIFICANCE: The importance of the immune system in effective cancer treatment is widely recognized. We show that the new signal interceptors targeting the JAK-STAT5 pathway may have dangerous side effects that must be taken into account in clinical trials: inhibiting JAK-STAT5 has the potential to promote tumor growth by enhancing NK-cell-mediated angiogenesis. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26873347 DOI: 10.1158/2159-8290.CD-15-0732
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397